Dr. Coffin invented and developed IMLYGIC while at Biovex Inc. Biovex, also founded by Dr Coffin, originally spun out of his research group at University College London in 1999 before being acquired by Amgen in 2011. Since the Biovex acquisition, Dr. Coffin has remained active in the cancer immunotherapy field and recently founded Replimune Ltd. a company developing next generation oncolytic immunotherapy products.
"On behalf of all of Replimune's investors, we congratulate Rob for his achievement and this recognition of his pioneering role in the field of immuno-oncology," said Jason Rhodes, partner at Atlas Venture. "We are excited to be working with Rob as he and the Replimune team create transformational oncolytic immunotherapies that will greatly advance patient care."
About Replimune Ltd
Replimune, headquartered in Oxford UK and with offices in the UK and MA, was founded in April 2015 to develop the next generation of 'oncolytic immunotherapies' for the treatment of cancer. Replimune is developing novel, proprietary products intended to improve both the direct anti-tumor effects of selective virus replication and the potency of the immune response to the tumor antigens released. Replimune intends to progress these therapies rapidly through clinical trials and to combine these with other immuno-oncology products with complementary mechanisms of action at an early stage.
About Oncolytic Therapy
Oncolytic immunotherapy is an emerging class of cancer therapeutics which exploit the ability of viruses to selectively replicate in and kill tumor tissue, while at the same time induce a potent, patient-specific, anti-tumor immune response. Oncolytic viruses have the unique ability to generate an autologous vaccine to the patient's particular complement of tumor antigens, including neoantigens, in situ in the patient with a truly off-the-shelf approach. While clear single agent clinical activity has been achieved with oncolytic immunotherapy, it is anticipated that particular synergy may be observed in combination with immune checkpoint blockade and other immune-modulatory approaches.
SOURCE Replimune Ltd